Business
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time Recursion has been ranked by ISS. The ISS ESG Corporate Rating provides an assessment of a company's environmental, social, and governance activity. A Prime Rating is awarded to companies with ESG performance above a sector-specific threshold and is defined by ISS as \"absolute best in class\".\n\n \n \n \n \n \n \n\n \n\"We are proud to receive a Prime Rating by ISS for ESG,\" said Chris Gibson, Ph.D., Co-Founder & CEO of Recursion. \"As a company looking to revolutionize the drug discovery industry, it is critical that we focus on building a sustainable culture that not only fosters interdisciplinary work across healthcare and technology, but also achieves the highest standards in mitigating our environmental impact and creating an inclusive, diverse, and equitable workplace in order to drive long-term success in the years to come.\"\nAdditionally, on September 29, 2022, Recursion plans to participate in the Goldman Sachs Global Sustainability Forum to share more about its ESG strategy and connect with the ESG investor community.\nRecursion's Prime Rating from ISS follows the release of Recursion's first ESG report earlier this year, which outlines the Company's approach, practices and goals in several important areas. As part of the report, Recursion announced long-term commitments focused on net-zero greenhouse gas emissions, workforce diversity, and philanthropy.\nThe full 2022 Recursion ESG Report can be found here.\nMore information on ISS ESG Corporate Ratings can be found here.\nAbout RecursionRecursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding...